세계의 소마토스타틴 유사체(Somatostatin Analogs) 시장 보고서(2025년)

A somatostatin analog is a man-made version of somatostatin, a natural hormone that regulates the production of various hormones in the body, such as serotonin and growth hormone. The primary purpose of somatostatin analogs is to slow down the release of these hormones. These analogs are particularly employed to alleviate symptoms associated with carcinoid syndrome, which may include diarrhea and skin flushing.

The key somatostatin analogs in medical use are octreotide, lanreotide, and pasireotide. Octreotide is a medication designed to mimic the effects of somatostatin by blocking the release of growth hormones. It is commonly utilized in the treatment of specific conditions such as tumor-related diarrhea and flushing. These somatostatin analogs find applications in addressing various medical conditions, including acromegaly, Cushing's syndrome, neuroendocrine tumors, carcinoid syndrome, and others. The end users for these analogs include hospitals and pharmaceutical companies, emphasizing their significance in medical treatments and therapies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The somatostatin analogs market research report is one of a series of new reports from The Business Research Company that provides somatostatin analogs market statistics, including the somatostatin analogs industry global market size, regional shares, competitors with a somatostatin analogs market share, detailed somatostatin analogs market segments, market trends, and opportunities, and any further data you may need to thrive in the somatostatin analogs industry. This somatostatin analogs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The somatostatin analogs market size has grown strongly in recent years. It will grow from $6.73 billion in 2024 to $7.16 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increased net incidence, advancements in oncology research, clinical efficacy in symptom management, expansion of indications, patient preference for long-acting formulations.

The somatostatin analogs market size is expected to see strong growth in the next few years. It will grow to $9.44 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to continued rise in net incidence, research focus on rare diseases, development of combination therapies, advancements in personalized medicine, global health initiatives in cancer care. Major trends in the forecast period include global aging population, healthcare infrastructure development in emerging markets, strategic collaborations and partnerships, pricing pressures and reimbursement challenges, technological integration in healthcare.

The forecast of 7.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of advanced neuroendocrine tumor management by inflating prices of somatostatin analog therapies developed in France and Denmark, resulting in delayed symptom control and higher specialty pharmacy expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The somatostatin analogs market is expected to experience significant growth due to the increasing incidence of neuroendocrine tumors. Neuroendocrine tumors, originating in specialized neuroendocrine cells, can lead to excessive hormone production. Somatostatin analogs play a crucial role in regulating hormone levels, inhibiting tumor growth, and alleviating symptoms associated with carcinoid disease. For instance, in 2022, Cancer Australia reported approximately 5,437 new cases of neuroendocrine tumors in Australia, highlighting the prevalence of this condition. The rise in neuroendocrine tumor incidence is a key factor driving the expansion of the somatostatin analogs market.

The growth of the somatostatin analogs market is expected to be propelled by the increasing aging population. The demographic shift toward a higher proportion of individuals aged 65 and older is associated with a higher incidence of diseases that necessitate the use of somatostatin analogs. As of 2022, there were 771 million people aged 65 and above globally, constituting nearly 10% of the world's population, as reported by Visual Capitalist. This demographic trend contributes to a growing demand for pharmaceuticals, including somatostatin analogs, as they are commonly used in conditions prevalent among the elderly. Consequently, the expanding aging population is a significant driver for the growth of the somatostatin analogs market.

Major companies in the somatostatin analogs market are focused on developing advanced products, such as targeted radiopharmaceuticals, to improve the precision and effectiveness of cancer treatments, particularly for patients with somatostatin receptor-positive tumors. Targeted radiopharmaceuticals are specialized drugs that combine radiation-emitting isotopes with molecules designed to specifically bind to cancer cells, enabling precise delivery of therapeutic radiation to tumor sites while reducing exposure to surrounding healthy tissues. For example, in January 2024, Lantheus, a US-based company specializing in radiopharmaceuticals, launched Lutetium Lu-177 Dotatate. This radiolabeled somatostatin analog is used in peptide receptor radionuclide therapy (PRRT) for treating advanced somatostatin receptor-positive neuroendocrine tumors. Clinical studies have shown that it significantly improves progression-free survival and response rates compared to traditional somatostatin analogs like octreotide, making it a crucial option for patients whose disease has progressed despite previous treatments. Its targeted approach allows for effective tumor control while minimizing systemic exposure, enhancing the overall therapeutic profile for managing neuroendocrine malignancies.

Major companies in the somatostatin analogs market are concentrating on developing advanced products, such as oral selective agonists, to enhance patient compliance and improve the treatment of conditions linked to excess growth hormone, like acromegaly. Oral selective agonists are compounds designed to selectively activate specific receptors in the body when taken orally, resulting in targeted biological responses while minimizing effects on other receptor types. For instance, in September 2024, Crinetics Pharmaceuticals Inc., a US-based company focused on discovering and developing novel therapeutics for rare endocrine diseases and endocrine-related tumors, submitted a new drug application for paltusotine to treat acromegaly. Paltusotine is an oral, nonpeptide small-molecule agonist specifically targeting somatostatin receptor type 2 (SST2). This innovative drug offers a once-daily dosing regimen, improving patient compliance compared to traditional injectable somatostatin analogs like octreotide and lanreotide. Clinical studies have demonstrated that paltusotine effectively lowers insulin-like growth factor I (IGF-I) levels, presenting a promising alternative for patients needing long-term management of hormone hypersecretion.

In October 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, partnered with Philogen S.p.A. to enhance its portfolio and broaden access to innovative cancer treatments. This collaboration aims to commercialize the under-development skin cancer drug Nidlegy in Europe, Australia, and New Zealand. Philogen S.p.A. is an Italy-based biotechnology company dedicated to developing targeted therapeutics for oncology.

Major companies operating in the somatostatin analogs market include Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, Midatech Pharma plc, Crinetics Pharmaceuticals Inc., Peptron Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Bayer Aktiengesellschaft, Cadila Healthcare Limited, Amneal Pharmaceuticals Inc., Recordati S.p.A., Amryt Pharma plc, Ipsen Pharma SA, Fresenius Kabi AG, Chiasma Inc., Merck KGaA, Sanofi S.A., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Viatris Inc., AstraZeneca plc, Johnson & Johnson, Genentech Inc., OctreoPharm Sciences GmbH

North America was the largest region in the global somatostatin analogs treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the somatostatin analogs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the somatostatin analogs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The somatostatin analogs market consists of sales of sandostatin, sandostatin lar, olatuton, somatuline LA, and somatuline autogel. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Somatostatin Analogs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on somatostatin analogs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for somatostatin analogs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The somatostatin analogs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Octreotide; Lanreotide; Pasireotide
• 2) By Treatment: Acromegaly; Cushing's Syndrome; Neuroendocrine Tumors; Carcinoid Syndrome; Other Treatments
• 3) By End User: Hospital; Pharmaceutical Companies
• Subsegments:
• 1) By Octreotide: Long-Acting Release (LAR) Formulations; Short-Acting Formulations
• 2) By Lanreotide: Depot Formulations; Injectable Formulations
• 3) By Pasireotide: Long-Acting Injectable Formulations; Subcutaneous Formulations
• Companies Mentioned: Novartis International AG; Pfizer Inc.; Sun Pharmaceutical Industries Limited; Midatech Pharma plc; Crinetics Pharmaceuticals Inc.; Peptron Inc.; Teva Pharmaceutical Industries Ltd.; Camurus AB; Bayer Aktiengesellschaft; Cadila Healthcare Limited; Amneal Pharmaceuticals Inc.; Recordati S.p.A.; Amryt Pharma plc; Ipsen Pharma SA; Fresenius Kabi AG; Chiasma Inc.; Merck KGaA; Sanofi S.A.; Sandoz International GmbH; Takeda Pharmaceutical Company Limited; Viatris Inc.; AstraZeneca plc; Johnson & Johnson; Genentech Inc.; OctreoPharm Sciences GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Somatostatin Analogs Market Characteristics

3. Somatostatin Analogs Market Trends And Strategies

4. Somatostatin Analogs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Somatostatin Analogs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Somatostatin Analogs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Somatostatin Analogs Market Growth Rate Analysis
• 5.4. Global Somatostatin Analogs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Somatostatin Analogs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Somatostatin Analogs Total Addressable Market (TAM)

6. Somatostatin Analogs Market Segmentation

• 6.1. Global Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Octreotide
• Lanreotide
• Pasireotide
• 6.2. Global Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acromegaly
• Cushing's Syndrome
• Neuroendocrine Tumors
• Carcinoid Syndrome
• Other Treatments
• 6.3. Global Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Pharmaceutical Companies
• 6.4. Global Somatostatin Analogs Market, Sub-Segmentation Of Octreotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Long-Acting Release (LAR) Formulations
• Short-Acting Formulations
• 6.5. Global Somatostatin Analogs Market, Sub-Segmentation Of Lanreotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Depot Formulations
• Injectable Formulations
• 6.6. Global Somatostatin Analogs Market, Sub-Segmentation Of Pasireotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Long-Acting Injectable Formulations
• Subcutaneous Formulations

7. Somatostatin Analogs Market Regional And Country Analysis

• 7.1. Global Somatostatin Analogs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Somatostatin Analogs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Somatostatin Analogs Market

• 8.1. Asia-Pacific Somatostatin Analogs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Somatostatin Analogs Market

• 9.1. China Somatostatin Analogs Market Overview
• 9.2. China Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Somatostatin Analogs Market

• 10.1. India Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Somatostatin Analogs Market

• 11.1. Japan Somatostatin Analogs Market Overview
• 11.2. Japan Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Somatostatin Analogs Market

• 12.1. Australia Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Somatostatin Analogs Market

• 13.1. Indonesia Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Somatostatin Analogs Market

• 14.1. South Korea Somatostatin Analogs Market Overview
• 14.2. South Korea Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Somatostatin Analogs Market

• 15.1. Western Europe Somatostatin Analogs Market Overview
• 15.2. Western Europe Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Somatostatin Analogs Market

• 16.1. UK Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Somatostatin Analogs Market

• 17.1. Germany Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Somatostatin Analogs Market

• 18.1. France Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Somatostatin Analogs Market

• 19.1. Italy Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Somatostatin Analogs Market

• 20.1. Spain Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Somatostatin Analogs Market

• 21.1. Eastern Europe Somatostatin Analogs Market Overview
• 21.2. Eastern Europe Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Somatostatin Analogs Market

• 22.1. Russia Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Somatostatin Analogs Market

• 23.1. North America Somatostatin Analogs Market Overview
• 23.2. North America Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Somatostatin Analogs Market

• 24.1. USA Somatostatin Analogs Market Overview
• 24.2. USA Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Somatostatin Analogs Market

• 25.1. Canada Somatostatin Analogs Market Overview
• 25.2. Canada Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Somatostatin Analogs Market

• 26.1. South America Somatostatin Analogs Market Overview
• 26.2. South America Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Somatostatin Analogs Market

• 27.1. Brazil Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Somatostatin Analogs Market

• 28.1. Middle East Somatostatin Analogs Market Overview
• 28.2. Middle East Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Somatostatin Analogs Market

• 29.1. Africa Somatostatin Analogs Market Overview
• 29.2. Africa Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Somatostatin Analogs Market Competitive Landscape And Company Profiles

• 30.1. Somatostatin Analogs Market Competitive Landscape
• 30.2. Somatostatin Analogs Market Company Profiles
  • 30.2.1. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sun Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Midatech Pharma plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Crinetics Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Somatostatin Analogs Market Other Major And Innovative Companies

• 31.1. Peptron Inc.
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Camurus AB
• 31.4. Bayer Aktiengesellschaft
• 31.5. Cadila Healthcare Limited
• 31.6. Amneal Pharmaceuticals Inc.
• 31.7. Recordati S.p.A.
• 31.8. Amryt Pharma plc
• 31.9. Ipsen Pharma SA
• 31.10. Fresenius Kabi AG
• 31.11. Chiasma Inc.
• 31.12. Merck KGaA
• 31.13. Sanofi S.A.
• 31.14. Sandoz International GmbH
• 31.15. Takeda Pharmaceutical Company Limited

32. Global Somatostatin Analogs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Somatostatin Analogs Market

34. Recent Developments In The Somatostatin Analogs Market

35. Somatostatin Analogs Market High Potential Countries, Segments and Strategies

• 35.1 Somatostatin Analogs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Somatostatin Analogs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Somatostatin Analogs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer